Summary
Pfizer Inc. (PFE) filed an 8-K on March 2, 2005, detailing executive compensation decisions made by its Compensation Committee on February 24, 2005. These decisions cover annual base salaries, cash bonus awards for fiscal year 2004, and the granting of long-term incentive awards, including stock options and performance-contingent share awards for the period of January 1, 2005, to December 31, 2009. The filing provides transparency into the compensation packages for key executive officers, including the Chairman and CEO, and other senior leadership. Investors can find details on specific salary adjustments effective April 1, 2005, and bonus amounts awarded based on company and individual performance against financial and strategic objectives. The report also outlines the payouts of previously awarded long-term incentives based on total shareholder return and earnings per share relative to peer companies, as well as new grants of stock options and performance-contingent shares. This information is crucial for understanding executive alignment with shareholder interests and the company's incentive structures.
Key Highlights
- 1Pfizer's Compensation Committee approved annual base salaries and cash bonus awards for 2004 and 2005 for its Named Executive Officers (NEOs).
- 2Base salary changes are effective April 1, 2005, with specific amounts detailed for key executives like the CEO, CFO, and heads of Global Pharmaceuticals and R&D.
- 3Annual incentive awards for 2004 were paid based on the company's performance and individual executive assessments against set objectives, with maximum bonus tied to Adjusted Net Income.
- 4Long-term incentive awards earned for performance periods ending December 31, 2004, and December 31, 2003, were paid out in February 2005, reflecting performance relative to peer companies.
- 5New grants of ten-year non-qualified stock options were issued to NEOs in 2005 at an exercise price of $26.20.
- 6Performance-contingent share awards were granted for the period January 1, 2005, to December 31, 2009, with payouts dependent on total shareholder return and diluted EPS growth relative to industry peers.
- 7No restricted stock grants were made in 2005; however, grants from 2004 are detailed, vesting in March 2007.